Bioavailability and Pharmacokinetics of Calcium Dobesilate (Doxium®) in the Nasal Mucosal Tissue, Saliva and Blood of Treated Patients

Launched by UNIVERSITY HOSPITAL, GENEVA · Jun 10, 2021

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• 1. Patients treated with calcium dobesilate (1000-2000mg/day), at any time on treatment or for whom initiation of treatment has been prescribed, for one of its Swiss indications:
• • Microangiopathies, in particular diabetic retinopathy.
• • Clinical symptoms of chronic venous insufficiency of the legs (pains, cramps, paraesthesia, oedemas, stasis dermatitis), superficial thrombophlebitis in adjuvant treatment.
• • Haemorrhoidal syndrome, post-thrombotic syndrome, microcirculatory disorders of arteriovenous origin.
• • 2. Male or female
• • 3. Aged ≥18 years
• • 4. Subject has provided the appropriate written informed consent. Subject must provide written informed consent before any study-specific procedures are performed
• Exclusion Criteria:
• • 1. Known sensitivity to calcium dobesilate
• • 2. Currently suffering from or treated for a nasal condition, e.g., a runny, congested nose, nasal infection, or an oral condition, e.g., oral infection, including suspected SARS-CoV-2 infection
• • 3. Currently treated with a nasal or an oral product, or any treatment with the same active substance as in CaD (e.g., doxiproct, dicynone)
• • 4. Current participation in any other investigational drug study
• • 5. Only for patients already on CaD treatment: treatment with CaD initiated within last 7 days only
• • 6. Only for patients starting CaD treatment: treatment with CaD within last 30 days